Please assess the completion status of the following clinical trial:

Trial Title: Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Male aged ≥ 18 years~* Life expectancy ≥ 6 months~* Histologically- or cytologically-confirmed adenocarcinoma of the prostate~* Metastatic disease or prior history of metastases, as documented by positive bone scan or metastatic lesions on CT or MRI~* Prostate cancer progression, as documented by PSA according to PCWG2 or radiographic progression according to RECIST criteria version 1.1~* Progression must have been during or after docetaxel based chemotherapy.~* Surgically or medically castrated, with testosterone levels of \< 50 ng/dL (\< 2.0 nM). If the patient is currently being treated with LHRH agonists (patient who have not undergone an orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and treatment must be continued throughout the study.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2~* Hemoglobin ≥ 10.0 g/dL~* Platelet count ≥100,000 microliters~* Serum creatinine ≤ 2, OR a calculated creatinine clearance ≥ 40 mL/min~* Serum bilirubin \< 1.5 x ULN (except for patients Gilbert's disease)~* AST or ALT \< 2.5 x ULN~* Able to swallow the study drug whole as a tablet~* Willing and able to provide written informed consent~EXCLUSION CRITERIA~* Known brain metastasis~* Radiation therapy within 4 weeks of Cycle 1, Day 1~* Prior systemic treatment with an azole drug (eg, fluconazole, ketoconazole) within 4 weeks of Cycle 1, Day 1~* Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1 (patients whose PSA did not decline for ≥ 3 months months in response to antiandrogen given as a 2nd line or later intervention will require only a 2-week washout prior to Cycle 1,Day 1)~* Prior Bicalutamide (Casodex), nilutamide (Nilandron) treatment within 6 weeks of Cycle 1 Day 1 (patients whose PSA did not decline for ≥ 3 months in response to antiandrogen given as a 2nd line or later intervention will require only a 2-week washout prior to Cycle 1 Day 1)~* Known active or symptomatic viral hepatitis or chronic liver disease~* Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic events in the past 6 months; severe or unstable angina~* Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 24 months~* Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1~* Any condition which, in the opinion of the investigator, would preclude the patient's participation in this trial.~* No more than 3 prior chemotherapy regimens.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Itraconazole (Type: EXPERIMENTAL): 600 mg/day oral (PO)

Based on this trial design, predict the completion outcome and termination type (if applicable).